



January 3, 2022

Web Announcement 2670

Silver State Scripts Board (SSSB) Makes Changes to Preferred Drug List (PDL) Effective January 3, 2022

The Silver State Scripts Board (SSSB) met on September 23, 2021, and voted to adopt the following changes to the Nevada Medicaid Preferred Drug List (PDL) effective January 3, 2022.

The complete PDL is posted on the [“Preferred Drug List”](#) webpage.

Drug Class/Program	Changes
Anti-infective Agents – Aminoglycosides – Inhaled Aminoglycosides	Tobramycin nebulizer 300mg/4mL added as non-preferred
Biologic Response Modifiers – Immunomodulators – Targeted Immunomodulators	Enspryng® added as non-preferred Xeljanz XR® moved to non-preferred
Biologic Response Modifiers – Multiple Sclerosis Agents – Injectable	Rebif® moved to non-preferred. Coverage of Rebif® for current users will be preauthorized for continuation of therapy.
Biologic Response Modifiers – Multiple Sclerosis Agents – Oral	Ponvory® added as non-preferred
Cardiovascular Agents – Antilipemics – Bile Acid Sequestrants	Colesevelam added as non-preferred
Cardiovascular Agents – Antilipemics – HMG-CoA Reductase Inhibitors (Statins)	Ezetimibe/Simvastatin moved to preferred Vytorin® moved to non-preferred
Dermatological Agents – Topical Analgesics	Lenzapro® added as non-preferred Lidocaine 5% patch moved to non-preferred Lidoderm® moved to preferred
Dermatological Agents – Topical Antineoplastics – Topical Retinoids	Arazlo® added as non-preferred Epiduo® moved to preferred
Gastrointestinal Anti-inflammatory Agents – Gastrointestinal Enzymes	Pancreaze® moved to preferred
Hormones and Hormone Modifiers – Antidiabetic Agents – Incretin Mimetics Agents	Rybelsus® moved to preferred
Hormones and Hormone Modifiers – Antidiabetic Agents – Insulins (Vials, Pens and Inhaled)	Insulin Aspart Mix moved to preferred Insulin Lispro Mix moved to preferred
Musculoskeletal Agents – Antigout Agents	Febuxostat moved to preferred Uloric® moved to non-preferred
Neurological Agents – Anti-Migraine Agents – Calcitonin Gene Related Peptide (CGRP) Receptor Antagonists	Aimovig® moved to preferred Ubrelvy® moved to non-preferred

Drug Class/Program	Changes
Neurological Agents – Anti-Migraine Agents – Serotonin Receptor Agonists	Frova® moved to preferred Relpax® moved to preferred Zolmitriptan nasal spray moved to preferred Zomig® spray moved to non-preferred
Neurological Agents – Antiparkinsonian Agents – Dopamine Precursors	Carbidopa/Levodopa/Entacapone moved to preferred Stalevo® moved to non-preferred
Ophthalmic Agents – Ophthalmic Antihistamines	Azelastine moved to preferred Lastacraft® moved to preferred Olopatadine (drop/sol) moved to preferred Pazeo® moved to non-preferred
Psychotropic Agents – ADHD Agents	Atomoxetine moved to preferred Qelbree® added as preferred
Psychotropic Agents – Psychostimulants – Narcolepsy Agents	Armodafinil moved to non-preferred Xywav® added as non-preferred
Respiratory Agents – Long Acting/ Maintenance Therapy	Asmanex® moved to non-preferred Bevespi® moved to non-preferred
Respiratory Agents – Short-Acting/Rescue Therapy	ProAir Digihaler® added as non-preferred